Literature DB >> 23785123

Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44.

Søren E Degn1, Lisbeth Jensen, Tomasz Olszowski, Jens C Jensenius, Steffen Thiel.   

Abstract

The lectin pathway of complement is an integral component of innate immunity. It is activated upon binding of mannan-binding lectin (MBL) or ficolins (H-, L-, and M-ficolin) to suitable ligand patterns on microorganisms. MBL and ficolins are polydisperse homo-oligomeric molecules, found in complexes with MBL-associated serine proteases (MASP-1, -2, and -3) and MBL-associated proteins (MAp19 and MAp44). This scenario is far more complex than the well-defined activation complex of the classical pathway, C1qC1r(2)C1s(2), and the composition of the activating complexes of the lectin pathway is ill defined. We and other investigators recently demonstrated that both MASP-1 and MASP-2 are crucial to lectin pathway activation. MASP-1 transactivates MASP-2 and, although MASP-1 also cleaves C2, MASP-2 cleaves both C4 and C2, allowing formation of the C3 convertase, C4bC2a. Juxtaposition of MASP-1 and MASP-2 during activation must be required for transactivation. We previously presented a possible scenario, which parallels that of the classical pathway, in which MASP-1 and MASP-2 are found together in the same MBL or ficolin complex. In this study, we demonstrate that, although MASPs do not directly form heterodimers, the addition of MBL or ficolins allows the formation of MASP-1-MASP-2 co-complexes. We find that such co-complexes have a functional role in activating complement and are present in serum at varying levels, impacting on the degree of complement activation. This raises the novel possibility that MAp44 may inhibit complement, not simply by brute force displacement of MASP-2 from MBL or ficolins, but by disruption of co-complexes, hence impairing transactivation. We present support for this contention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23785123     DOI: 10.4049/jimmunol.1300780

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

Review 2.  Targeting mechanisms at sites of complement activation for imaging and therapy.

Authors:  V Michael Holers
Journal:  Immunobiology       Date:  2015-04-30       Impact factor: 3.144

Review 3.  Gut Microbiota Disorder, Gut Epithelial and Blood-Brain Barrier Dysfunctions in Etiopathogenesis of Dementia: Molecular Mechanisms and Signaling Pathways.

Authors:  Menizibeya O Welcome
Journal:  Neuromolecular Med       Date:  2019-05-21       Impact factor: 3.843

4.  Complement activation by ligand-driven juxtaposition of discrete pattern recognition complexes.

Authors:  Søren E Degn; Troels R Kjaer; Rune T Kidmose; Lisbeth Jensen; Annette G Hansen; Mustafa Tekin; Jens C Jensenius; Gregers R Andersen; Steffen Thiel
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

5.  Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAp44 expression.

Authors:  Nirmal K Banda; Gaurav Mehta; Troels R Kjaer; Minoru Takahashi; Jerome Schaack; Thomas E Morrison; Steffen Thiel; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2014-07-28       Impact factor: 5.422

6.  A New Ligand-Based Method for Purifying Active Human Plasma-Derived Ficolin-3 Complexes Supports the Phenomenon of Crosstalk between Pattern-Recognition Molecules and Immunoglobulins.

Authors:  Aleksandra Man-Kupisinska; Mateusz Michalski; Anna Maciejewska; Anna S Swierzko; Maciej Cedzynski; Czeslaw Lugowski; Jolanta Lukasiewicz
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

7.  Low level of MAp44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients.

Authors:  Julia Smedbråten; Geir Mjøen; Anders Hartmann; Anders Åsberg; Halvor Rollag; Tom Eirik Mollnes; Leiv Sandvik; Morten W Fagerland; Steffen Thiel; Solbjørg Sagedal
Journal:  BMC Nephrol       Date:  2016-10-18       Impact factor: 2.388

8.  CsMAP34, a teleost MAP with dual role: A promoter of MASP-assisted complement activation and a regulator of immune cell activity.

Authors:  Mo-Fei Li; Jun Li; Li Sun
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

9.  Extensive Basal Level Activation of Complement Mannose-Binding Lectin-Associated Serine Protease-3: Kinetic Modeling of Lectin Pathway Activation Provides Possible Mechanism.

Authors:  Gábor Oroszlán; Ráhel Dani; András Szilágyi; Péter Závodszky; Steffen Thiel; Péter Gál; József Dobó
Journal:  Front Immunol       Date:  2017-12-18       Impact factor: 7.561

10.  COLEC10 is mutated in 3MC patients and regulates early craniofacial development.

Authors:  Mustafa M Munye; Anna Diaz-Font; Louise Ocaka; Maiken L Henriksen; Melissa Lees; Angela Brady; Dagan Jenkins; Jenny Morton; Soren W Hansen; Chiara Bacchelli; Philip L Beales; Victor Hernandez-Hernandez
Journal:  PLoS Genet       Date:  2017-03-16       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.